Detalhe da pesquisa
1.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Diabetes Obes Metab
; 26(3): 961-970, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38073422
2.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Diabetes Obes Metab
; 25(6): 1503-1511, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36722623
3.
Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes?
Endocr J
; 69(5): 495-509, 2022 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34819409
4.
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Diabetes Obes Metab
; 22(3): 458-462, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31486230
5.
Effect of switching from pioglitazone to the sodium glucose co-transporter-2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type 2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
Diabetes Obes Metab
; 21(3): 710-714, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30311367
6.
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
Endocr J
; 65(2): 141-150, 2018 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29093280
7.
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Cardiovasc Diabetol
; 16(1): 125, 2017 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29017497
8.
Improvement of ß-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
J Clin Endocrinol Metab
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695547
9.
Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History.
JMA J
; 5(2): 230-239, 2022 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35611223
10.
The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).
J Diabetes Investig
; 13(11): 1834-1841, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35735780
11.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study).
BMJ Open
; 12(5): e056885, 2022 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35584872
12.
Association between Obesity and Intake of Different Food Groups among Japanese with Type 2 Diabetes Mellitus-Japan Diabetes Clinical Data Management Study (JDDM68).
Nutrients
; 14(15)2022 Jul 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35893888
13.
Higher Iron Intake Is Independently Associated with Obesity in Younger Japanese Type-2 Diabetes Mellitus Patients.
Nutrients
; 14(1)2022 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35011086
14.
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Diabetes Res Clin Pract
; 192: 110091, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36174777
15.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
J Diabetes Investig
; 12(8): 1395-1399, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33325645
16.
Comparing Associations of Dietary Energy Density and Energy Intake, Macronutrients with Obesity in Patients with Type 2 Diabetes (JDDM 63).
Nutrients
; 13(9)2021 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34579047
17.
Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
Diabetes Res Clin Pract
; 180: 109069, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34563585
18.
Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
Diabetes Ther
; 12(3): 955-964, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33491111
19.
Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes.
J Diabetes Investig
; 12(2): 176-183, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32593203
20.
Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
J Diabetes Investig
; 12(7): 1272-1277, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33131199